GHRS — GH Research PLC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1855129 ·
Last close
$28.07
Market Cap
$1.93B
52W High
$31.00
52W Low
$19.52
ADV30
292,340
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -18,748,000 | -18,967,000 | 275,267,000 | 242,652,000 | 11,890,000 |
| Dec 2025 | 0 | — | -16,699,000 | -14,137,000 | 288,230,000 | 246,251,000 | 8,527,000 |
| Sep 2025 | 0 | — | -16,535,000 | -14,020,000 | 302,022,000 | 249,654,000 | 10,625,000 |
| Jun 2025 | 0 | — | -14,691,000 | -9,289,000 | 313,428,000 | 253,873,000 | 10,249,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,552,000
Investing CF
$46,172,000
Financing CF
$139,651,000
CapEx
$-121,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.80
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-154,425,000
Inventory
—
Receivables
$1,295,000
ST Investments
$34,457,000
EBIT TTM
$-48,223,000
Pretax Income TTM
$-48,258,000
Interest Exp TTM
$35,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -60,676,000 | -48,258,000 | 288,230,000 | 8,527,000 | — | -43,552,000 |
| Dec 2024 | 0 | -50,246,000 | -38,961,000 | 188,273,000 | 9,322,000 | — | -42,285,000 |
| Dec 2023 | 0 | -41,221,000 | -35,587,000 | 226,300,000 | 7,332,000 | — | -33,336,000 |
| Dec 2022 | 0 | -30,675,000 | -22,456,000 | 254,362,000 | 4,546,000 | — | -26,199,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.90
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HCM | HUTCHMED (China) Ltd | $1.93B | $11.13 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.91B | $14.88 | — |
| NBTX | Nanobiotix S.A. | $1.95B | $38.38 | — |
| TYRA | Tyra Biosciences, Inc. | $1.90B | $31.88 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.96B | $40.98 | — |
News headlines (Yahoo Finance, 1h cache)
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
2026-07-27 14:38 · Yahoo
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
2026-07-16 17:53 · Yahoo
Why Psychedelic stocks are surging today
2026-07-16 11:44 · Yahoo
GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)
2026-07-16 10:33 · Yahoo
The Race to Commercialize the World’s Most Powerful Psychedelic
2026-07-14 19:00 · Yahoo
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
2026-07-13 18:59 · Yahoo
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?
2026-07-02 15:28 · Yahoo
AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs
2026-07-02 15:09 · Yahoo
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026
2026-07-02 14:50 · Yahoo
H.C. Wainwright Maintains Buy Rating on GH Research (GHRS)
2026-06-05 21:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.